BACKGROUND: p300 is a transcriptional regulator that is involved in fundamental processes such as cell proliferation, cell differentiation, and tumor progression. However, its role and clinical significance in resectable esophageal squamous cell carcinoma (ESCC) has not been elucidated. The purpose of this study was to explore whether there was a correlation between the expression of p300 by immunohistochemistry and the clinical outcome of a group of patients with ESCC treated with surgical resection. METHODS: Tissue microarray that included 240 surgically resected ESCC specimens and 56 cases of paracancerous tissues was successfully generated for immunohistochemical evaluation. The clinical and prognostic significance of p300 expression was analyzed statistically. Kaplan-Meier analysis was used to compare the postoperative survival between groups. RESULTS: The expression frequency and expression levels of p300 were significantly higher in ESCC specimens (62.5%, 150 of 240) than in normal esophageal mucosa (8.9%, 5 of 56; p<0.001). Increased p300 expression was associated with higher histologic grade (p=0.012), T category (p=0.032), and N category (p=0.013). Patients with low expression of p300 demonstrated higher overall survival compared with those with high expression of p300 (mean, 80.0 months versus 56.9 months; p<0.001). A similar result was observed for disease-free survival (mean, 78.3 months versus 53.1 months; p<0.001). Furthermore, p300 expression could stratify the patient survival (disease-free survival and overall survival) in stage II (p=0.002, 0.003, respectively). Multivariate analysis showed that the level of p300 expression was an independent prognostic factor in ESCC (relative risk, 1.658; p=0.017). CONCLUSIONS: High expression of p300 suggests poor prognosis for patients with resectable ESCC.
BACKGROUND:p300 is a transcriptional regulator that is involved in fundamental processes such as cell proliferation, cell differentiation, and tumor progression. However, its role and clinical significance in resectable esophageal squamous cell carcinoma (ESCC) has not been elucidated. The purpose of this study was to explore whether there was a correlation between the expression of p300 by immunohistochemistry and the clinical outcome of a group of patients with ESCC treated with surgical resection. METHODS: Tissue microarray that included 240 surgically resected ESCC specimens and 56 cases of paracancerous tissues was successfully generated for immunohistochemical evaluation. The clinical and prognostic significance of p300 expression was analyzed statistically. Kaplan-Meier analysis was used to compare the postoperative survival between groups. RESULTS: The expression frequency and expression levels of p300 were significantly higher in ESCC specimens (62.5%, 150 of 240) than in normal esophageal mucosa (8.9%, 5 of 56; p<0.001). Increased p300 expression was associated with higher histologic grade (p=0.012), T category (p=0.032), and N category (p=0.013). Patients with low expression of p300 demonstrated higher overall survival compared with those with high expression of p300 (mean, 80.0 months versus 56.9 months; p<0.001). A similar result was observed for disease-free survival (mean, 78.3 months versus 53.1 months; p<0.001). Furthermore, p300 expression could stratify the patient survival (disease-free survival and overall survival) in stage II (p=0.002, 0.003, respectively). Multivariate analysis showed that the level of p300 expression was an independent prognostic factor in ESCC (relative risk, 1.658; p=0.017). CONCLUSIONS: High expression of p300 suggests poor prognosis for patients with resectable ESCC.
Authors: Bo Ram Kim; Etienne Coyaud; Estelle M N Laurent; Jonathan St-Germain; Emily Van de Laar; Ming-Sound Tsao; Brian Raught; Nadeem Moghal Journal: Mol Cell Proteomics Date: 2017-08-09 Impact factor: 5.911
Authors: Alexander M Taylor; Alexandre Côté; Michael C Hewitt; Richard Pastor; Yves Leblanc; Christopher G Nasveschuk; F Anthony Romero; Terry D Crawford; Nico Cantone; Hariharan Jayaram; Jeremy Setser; Jeremy Murray; Maureen H Beresini; Gladys de Leon Boenig; Zhongguo Chen; Andrew R Conery; Richard T Cummings; Leslie A Dakin; E Megan Flynn; Oscar W Huang; Susan Kaufman; Patricia J Keller; James R Kiefer; Tommy Lai; Yingjie Li; Jiangpeng Liao; Wenfeng Liu; Henry Lu; Eneida Pardo; Vickie Tsui; Jian Wang; Yongyun Wang; Zhaowu Xu; Fen Yan; Dong Yu; Laura Zawadzke; Xiaoqin Zhu; Xiaoyu Zhu; Robert J Sims; Andrea G Cochran; Steve Bellon; James E Audia; Steven Magnuson; Brian K Albrecht Journal: ACS Med Chem Lett Date: 2016-03-15 Impact factor: 4.345